Thinly traded nano cap Annovis Bio (ANVS +22.6%)
bucks the broad market’s bearishness, albeit on turnover of only 54K
shares. After the close yesterday, CEO Maria Maccecchini, Ph.D., hosted
an online Q&A session about recent developments at the company.
Its top three pipeline candidates all treat
neurodegenerative disorders, principally Alzheimer’s and Parkinson’s
diseases, based on the inhibition of neurotoxic proteins, tau and alpha-synuclein.
https://seekingalpha.com/news/3561033-annovis-up-23-after-webinar-on-neurodegeneration-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.